328 related articles for article (PubMed ID: 29106516)
21. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
22. A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany.
Jakobs F; Wingen-Heimann SM; Jeck J; Kron A; Cornely OA; Kron F
BMC Health Serv Res; 2021 Sep; 21(1):939. PubMed ID: 34496836
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
Birch T; Golan Y; Rizzardini G; Jensen E; Gabryelski L; Guris D; Dorr MB
J Antimicrob Chemother; 2018 Sep; 73(9):2524-2528. PubMed ID: 29788418
[TBL] [Abstract][Full Text] [Related]
24. Bezlotoxumab for the Prevention of
Chahine EB; Cho JC; Worley MV
Consult Pharm; 2018 Feb; 33(2):89-97. PubMed ID: 29409575
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.
Merlo G; Graves N; Brain D; Connelly LB
J Gastroenterol Hepatol; 2016 Dec; 31(12):1927-1932. PubMed ID: 27043242
[TBL] [Abstract][Full Text] [Related]
26. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
27.
Asempa TE; Nicolau DP
Clin Interv Aging; 2017; 12():1799-1809. PubMed ID: 29123385
[TBL] [Abstract][Full Text] [Related]
28. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland.
Oksi J; Aalto A; Säilä P; Partanen T; Anttila VJ; Mattila E
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1947-1952. PubMed ID: 31359254
[TBL] [Abstract][Full Text] [Related]
29. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
[TBL] [Abstract][Full Text] [Related]
30. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
31. Bezlotoxumab for the prevention of Clostridium difficile recurrence.
Couture-Cossette A; Carignan A; Ilangumaran S; Valiquette L
Expert Opin Biol Ther; 2017 Nov; 17(11):1439-1445. PubMed ID: 28805081
[TBL] [Abstract][Full Text] [Related]
32. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.
Luo Y; Lucas AL; Grinspan AM
Dig Dis Sci; 2020 Apr; 65(4):1125-1133. PubMed ID: 31493042
[TBL] [Abstract][Full Text] [Related]
33. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
[TBL] [Abstract][Full Text] [Related]
34. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2017 Jul; 53(7):385-392. PubMed ID: 28837182
[TBL] [Abstract][Full Text] [Related]
35. Genetic Association Reveals Protection against Recurrence of
Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
mSphere; 2020 May; 5(3):. PubMed ID: 32376702
[TBL] [Abstract][Full Text] [Related]
36. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.
Zeng Z; Zhao H; Dorr MB; Shen J; Wilcox MH; Poxton IR; Guris D; Li J; Shaw PM
Anaerobe; 2020 Feb; 61():102137. PubMed ID: 31846705
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines.
Rajasingham R; Enns EA; Khoruts A; Vaughn BP
Clin Infect Dis; 2020 Feb; 70(5):754-762. PubMed ID: 31001619
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
Ford DC; Schroeder MC; Ince D; Ernst EJ
Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
[TBL] [Abstract][Full Text] [Related]
39. Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent
Yee KL; Kleijn HJ; Kerbusch T; Matthews RP; Dorr MB; Garey KW; Wrishko RE
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455246
[TBL] [Abstract][Full Text] [Related]
40. Bezlotoxumab for Preventing Recurrent Clostridium difficile Infections.
Rounds J; Strain J
S D Med; 2017 Sep; 70(9):422-423. PubMed ID: 28863256
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]